Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability
Open Access
- 5 November 2020
- Vol. 12 (11), 3267
- https://doi.org/10.3390/cancers12113267
Abstract
Multiple myeloma (MM) cells consume huge amounts of glutamine and, as a consequence, the amino acid concentration is lower-than-normal in the bone marrow (BM) of MM patients. Here we show that MM-dependent glutamine depletion induces glutamine synthetase in stromal cells, as demonstrated in BM biopsies of MM patients, and reproduced in vitro by co-culturing human mesenchymal stromal cells (MSCs) with MM cells. Moreover, glutamine depletion hinders osteoblast differentiation of MSCs, which is also severely blunted by the spent, low-glutamine medium of MM cells, and rescued by glutamine restitution. Glutaminase and the concentrative glutamine transporter SNAT2 are induced during osteoblastogenesis in vivo and in vitro, and both needed for MSCs differentiation, pointing to enhanced the requirement for the amino acid. Osteoblastogenesis also triggers the induction of glutamine-dependent asparagine synthetase (ASNS), and, among non-essential amino acids, asparagine rescues differentiation of glutamine-starved MSCs, by restoring the transcriptional profiles of differentiating MSCs altered by glutamine starvation. Thus, reduced asparagine availability provides a mechanistic link between MM-dependent Gln depletion in BM and impairment of osteoblast differentiation. Inhibition of Gln metabolism in MM cells and supplementation of asparagine to stromal cells may, therefore, constitute novel approaches to prevent osteolytic lesions in MM.Keywords
This publication has 38 references indexed in Scilit:
- Genome engineering using the CRISPR-Cas9 systemNature Protocols, 2013
- Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete RemissionClinical Cancer Research, 2013
- Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cellsLeukemia, 2012
- Advances in the Biology and Treatment of Bone Disease in Multiple MyelomaClinical Cancer Research, 2011
- Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone diseaseExperimental Hematology, 2009
- Pathogenesis of myeloma bone diseaseLeukemia, 2008
- Myeloma cells and bone marrow osteoblast interactions: Role in the development of osteolytic lesions in multiple myelomaLeukemia & Lymphoma, 2007
- Multiple myeloma bone disease: pathophysiology of osteoblast inhibitionBlood, 2006
- Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiationBlood, 2005
- Expression of an N-Methyl-D-Aspartate-Type Receptor by Human and Rat Osteoblasts and Osteoclasts Suggests a Novel Glutamate Signaling Pathway in BoneBone, 1998